High-Flow Nasal Oxygen-Assisted Deep Extubation Versus Awake Extubation in Morbidly Obese Patients
HFNO-Assisted 'No-Touch' Deep Extubation Versus Conventional Awake Extubation in Morbidly Obese Patients Undergoing Elective Laparoscopic Surgery: A Prospective Randomized Controlled Trial
This prospective, randomized controlled trial aims to compare two methods of tracheal extubation after general anesthesia in adults with morbid obesity undergoing elective laparoscopic surgery.
A total of 120 patients will be randomly assigned to one of two groups. In the first group, the breathing tube will be removed while the patient remains deeply anesthetized, followed immediately by heated and humidified high-flow nasal oxygen (HFNO). Patients will then be allowed to awaken without unnecessary stimulation. In the second group, the breathing tube will be removed after the patient is fully awake, followed by conventional oxygen therapy through a face mask.
The primary objective is to determine whether HFNO-assisted deep extubation reduces the incidence of coughing during the first 15 minutes after extubation compared with conventional awake extubation.
The study will also assess respiratory complications, the need for airway interventions, hemodynamic changes, recovery times, and adverse events associated with the two extubation approaches.
The findings may help inform airway management strategies during recovery from general anesthesia in patients with morbid obesity.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Фаза
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Ahmed Maged Nadar, M. B. B. Ch
- Номер телефона: 01019510974
- Электронная почта: Ahmed.magednadar@yahoo.com
Учебное резервное копирование контактов
- Имя: Mina Mahrous Sobhy, M.D
- Номер телефона: 01025273637
- Электронная почта: mms12@fayoum.edu.eg
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Adult patients aged 18-60 years. • BMI ≥ 40 kg/m² (morbidly obese). • American Society of Anesthesiologists (ASA) physical status classification II-III.
Patients scheduled for elective laparoscopic surgery .
• Mallampati score I or II (anticipated non-difficult airway).
Exclusion Criteria:
- Patients with known or anticipated difficult airway (Mallampati III-IV, previous history of difficult intubation, limited mouth opening, or cervical spine immobility).
Patients with severe obstructive sleep apnea (OSA) on home CPAP/BiPAP therapy who cannot tolerate nasal cannula delivery systems.
• Active gastroesophageal reflux disease (GERD) with aspiration risk.
• Patients with significant cardiovascular disease (NYHA class III-IV heart failure, unstable angina, or recent myocardial infarction within 6 months).
• Patients with severe pulmonary disease (FEV₁ < 50% predicted, chronic hypercapnia, or oxygen-dependent respiratory failure).
• Emergency surgical procedures.
• Patients with nasal obstruction, facial deformity, or conditions precluding HFNO delivery.
• Pregnant patients.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Поддерживающая терапия
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Group D (Deep Extubation + HFNO Group)
Patients allocated to this group will undergo tracheal extubation while deeply anesthetized, after confirmation of adequate spontaneous ventilation and neuromuscular recovery (train-of-four ratio ≥0.9). Immediately after extubation, heated and humidified high-flow nasal oxygen (HFNO) will be administered at an initial flow rate of 40 L/min, adjustable up to 60 L/min as clinically indicated. Oxygen concentration will be titrated to maintain SpO₂ ≥92%. HFNO will be continued for 60 minutes in the post-anesthesia care unit (PACU). |
At the end of surgery, following adequate recovery from neuromuscular blockade (train-of-four ratio ≥0.9) and confirmation of adequate spontaneous ventilation, the endotracheal tube will be removed while the patient remains deeply anesthetized (end-tidal sevoflurane concentration ≥1.0 age-adjusted MAC). Immediately after extubation, heated and humidified high-flow nasal oxygen (HFNO) will be administered through nasal cannulae at an initial flow rate of 40 L/min, which may be increased to 60 L/min as clinically indicated. The initial FiO₂ will be 1.0 and subsequently titrated to maintain SpO₂ ≥92%. HFNO will continue for 60 minutes in the post-anesthesia care unit. Unnecessary stimulation during emergence will be avoided. |
|
Активный компаратор: Group A (Awake Extubation Group)
Patients allocated to this group will undergo conventional awake tracheal extubation after discontinuation of general anesthesia, once they regain consciousness, respond to verbal commands, and meet standard extubation criteria, including adequate spontaneous ventilation and neuromuscular recovery (train-of-four ratio ≥0.9). Following extubation, supplemental oxygen will be administered through a simple face mask at 8-10 L/min for 60 minutes in the post-anesthesia care unit (PACU). |
At the end of surgery, general anesthesia will be discontinued, and tracheal extubation will be performed after the patient regains consciousness, responds to verbal commands, and fulfills standard extubation criteria, including adequate spontaneous ventilation and neuromuscular recovery (train-of-four ratio ≥0.9). Following extubation, supplemental oxygen will be administered via a simple face mask at 8-10 L/min for 60 minutes in the post-anesthesia care unit. |
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Incidence of Coughing During Extubation and Early Emergence
Временное ограничение: During tracheal extubation and up to 15 minutes post-extubation
|
The proportion of patients experiencing at least one episode of coughing during tracheal extubation or within the first 15 minutes after extubation. Coughing will be recorded as a binary outcome (yes/no) for each participant, and the incidence will be compared between the two study groups. |
During tracheal extubation and up to 15 minutes post-extubation
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Severity of Coughing During Extubation and Early Emergence
Временное ограничение: During tracheal extubation and up to 15 minutes post-extubation
|
Cough severity will be assessed using the Modified Minogue Cough Scale, a four-grade ordinal scale: Grade 1, no coughing; Grade 2, mild coughing; Grade 3, moderate coughing; and Grade 4, severe coughing. Cough severity will be assessed during tracheal extubation and throughout the first 15 minutes after extubation. |
During tracheal extubation and up to 15 minutes post-extubation
|
|
Incidence of Laryngospasm
Временное ограничение: During emergence and up to 60 minutes after tracheal extubation
|
The proportion of participants who experience laryngospasm during emergence from general anesthesia or within the first 60 minutes after tracheal extubation. Laryngospasm will be recorded as present or absent (yes/no), and any episode will be classified as partial or complete. |
During emergence and up to 60 minutes after tracheal extubation
|
|
Incidence of Breath-Holding or Apnea
Временное ограничение: During emergence and up to 60 minutes after tracheal extubation
|
The proportion of participants experiencing at least one episode of breath-holding or apnea during emergence from general anesthesia or within the first 60 minutes after tracheal extubation. Events will be recorded as present or absent (yes/no), with the type of respiratory event documented when applicable. |
During emergence and up to 60 minutes after tracheal extubation
|
|
Heart Rate During Emergence and Early Postoperative Recovery
Временное ограничение: At pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation.
|
Heart rate (HR), measured in beats per minute (bpm), will be recorded at pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation. Heart rate measurements at the predefined time points will be compared between the two study groups. |
At pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation.
|
|
Mean Arterial Pressure During Emergence and Early Postoperative Recovery
Временное ограничение: At pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation.
|
Mean arterial pressure (MAP), measured in millimeters of mercury (mmHg), will be recorded at pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation. Mean arterial pressure measurements at the predefined time points will be compared between the two study groups. |
At pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation.
|
|
Time From Extubation to Full Orientation
Временное ограничение: From tracheal extubation until full orientation during emergence
|
From tracheal extubation until achievement of full orientation, assessed for up to 60 minutes after extubation. |
From tracheal extubation until full orientation during emergence
|
|
Length of Stay in the Post-Anesthesia Care Unit
Временное ограничение: From PACU admission to PACU discharge
|
From admission to the post-anesthesia care unit (PACU) until PACU discharge, assessed for up to 4 hours after admission. |
From PACU admission to PACU discharge
|
|
Incidence of Bronchospasm
Временное ограничение: During emergence and up to 60 minutes after tracheal extubation
|
The proportion of participants experiencing at least one clinically diagnosed episode of bronchospasm during emergence from general anesthesia or within the first 60 minutes after tracheal extubation. Bronchospasm will be recorded as present or absent (yes/no). |
During emergence and up to 60 minutes after tracheal extubation
|
Соавторы и исследователи
Спонсор
Спонсор
Следователи
Следователи
- Главный следователь: Mohamed Ahmed Hamed Ismail, MD, Fayoum University
- Директор по исследованиям: Abeer Shaaban Joda Morsi, MD, Fayoum University
Публикации и полезные ссылки
Общие публикации
- 2. Waheed Z, Amatul-Hadi F, Kooner A, Bhatti J, Afzal M, Ahmed R, et al. General anesthetic care of obese patients undergoing surgery: a review of current anesthetic considerations and recent advances. Cureus. 2023;15(7):e41565. 3. Pelosi P, Gregoretti C. Perioperative management of obese patients. Best Practice & Research: Clinical Anaesthesiology. 2010;24(2):211-225. 4. Rosén J, Frykholm P, Fors D. Effect of high-flow nasal oxygen on postoperative oxygenation in obese patients: a randomized controlled trial. Health Science Reports. 2022;5(3):e616. 5. Singh PA, Thong SY, Sivasankar R. Airway management in patients suffering from morbid obesity. Saudi Journal of Anaesthesia. 2022;16(3):314-321. 6. Adams JP, Murphy PG. Obesity in anaesthesia and intensive care. British Journal of Anaesthesia. 2000;85(1):91-108. 7. Smith HC, Kinsella SM, Sellers WFS. A comparison of deep versus awake tracheal extubation in adults: a randomized controlled trial. Regional Anesthesia & Pain Medicine. 2024. doi:10.1136/rapm-2024-105362. 8. Abdelmalak BB, Maheshwari A, Mascha EJ. Evaluation of "no touch" extubation technique on airway-related complications during emergence from general anesthesia. Egyptian Journal of Anaesthesia. 2012;28(2):135-141. 9. Wang YK, Li X, Wei SY, Lv X. The effect of high-flow nasal cannula oxygen therapy on preventing hypoxemia during deep sedation extubation after laparoscopic surgery: a prospective randomized controlled trial. BMC Anesthesiology. 2026. doi:10.1186/s12871-026-03735-w. 10. Petkar S, Wanjari D, Priya V. A comprehensive review on high-flow nasal cannula oxygen therapy in critical care: evidence-based insights and future directions. Cureus. 2024;16(8):e66264. 11. Ferrando C, Puig J, Serralta F, Jimenez V, Gutierrez A, García M, et al. High-flow nasal cannula oxygenation reduces postoperative hypoxemia in morbidly obese patients: a randomized controlled trial. Minerva Anestesiologica. 2019;85(10):1062-1070.
- Hardt K, Wappler F. Anesthesia for Morbidly Obese Patients. Dtsch Arztebl Int. 2023 Nov 17;120(46):779-785. doi: 10.3238/arztebl.m2023.0216.
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- M963
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
There is currently no plan to share individual participant data with external researchers. Study findings will be disseminated through scientific publications and presentations.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .